Schizophrenia: Processes in nerve cells observed
A step towards the goal of treating the causes of schizophrenia
Is it enough to treat the symptoms, or would we rather get to the causes of the illness? Up to now, schizophrenia has mainly been treated symptomatically, as little is known about the exact underlying processes. Researchers at the NMI Natural and Medical Sciences Institute in Reutlingen have succeeded in gaining a better understanding of the driving mechanisms of the disease. This offers opportunities for the development of new drugs. They have published their findings in the journal BMC Psychiatry.
Proteins play a central role in organisms in many respects. If they are incorrectly coded and/or do not carry out their tasks as planned, this can lead to diseases. This also applies to schizophrenia, in which nerve cells (neurons) develop incorrectly.
Early detection of faulty processes
A team of scientists at the NMI led by Aaron Stahl, Prof. Hansjürgen Volkmer and Dr. Markus Templin has now used DigiWest® technology to examine nerve cells during their development. They used patient-derived cells (provided by the University Hospital of Tübingen) from diseased and non-diseased individuals and subjected them to high-precision analysis.
“We have succeeded in observing neurons at an early stage of development. This enabled us to describe at an early stage that diseased cells develop worse and, above all, why,” explains Aaron Stahl, who conducts research at the NMI and the Faculty of Medicine at the University of Tübingen.
What happens in the nerve cells in schizophrenia?
The DigiWest® protein analyses provided an insight into important processes within diseased cells. It is now clear which processes are faulty. These include the repair of defective DNA. Cell cycle regulation, which determines the process of regular cell division, also no longer functions correctly. Finally, the so-called p53 regulation is significantly altered in these cells; it is already known that the protein p53 can trigger serious diseases such as cancer if it is incorrectly regulated. There appears to be a close connection between these malfunctions in the nerve cells and schizophrenia.
A step towards the goal of treating the causes of schizophrenia
“Thanks to our protein analyses, we now know much more about the actual triggers for schizophrenia. This is an important step on the way to possibly one day treating the disease closer to its causes with medication,” says NMI scientist Dr. Markus Templin, looking ahead. However, it will still take some time for science to achieve this goal.
Original publication
Aaron Stahl, Johanna Heider, Richard Wüst, Andreas J. Fallgatter, Katja Schenke-Layland, Hansjürgen Volkmer, Markus F. Templin; "Patient iPSC-derived neural progenitor cells display aberrant cell cycle control, p53, and DNA damage response protein expression in schizophrenia"; BMC Psychiatry, Volume 24, 2024-10-31
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Protein analytics
Protein analytics provides a deep insight into these complex macromolecules, their structure, function and interactions. It is essential for discovering and developing biopharmaceuticals, understanding disease mechanisms, and identifying therapeutic targets. Techniques such as mass spectrometry, Western blot and immunoassays allow researchers to characterize proteins at the molecular level, determine their concentration and identify possible modifications.
Topic world Protein analytics
Protein analytics provides a deep insight into these complex macromolecules, their structure, function and interactions. It is essential for discovering and developing biopharmaceuticals, understanding disease mechanisms, and identifying therapeutic targets. Techniques such as mass spectrometry, Western blot and immunoassays allow researchers to characterize proteins at the molecular level, determine their concentration and identify possible modifications.
